Julie M. Vose, MD, MBA, on Lymphoma: Novel Pathways for Targeted Agents
Pan Pacific Lymphoma Conference 2018Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses promising pathways for inhibitors—BTK, PI3K, EZH2, bcl-2—and the clinical trials for single agents and combinations that suggest their potential for lymphoma treatment.
Related Videos
John G. Gribben, MD, DSc, on The Tumor Microenvironment, Prognosis, and Outcome
John G. Gribben, MD, DSc, of the Barts Cancer Institute, discusses how understanding the role of the tumor microenvironment can help identify treatment targets, including com...
Andrew D. Zelenetz, MD, PhD, on NHL: Clinical Applications of Genomic Studies
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the various ways genomics can be used in diagnosing and treating non-Hodgkin lymphoma and the need...
R. Gregory Bociek, MD, on Ethical Considerations of Cancer Treatment
R. Gregory Bociek, MD, of the University of Nebraska Medical Center, discusses the controversial topic of euthanasia and physician-assisted suicide.
Susan Blumel, RN, BSN, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on Managing Toxicities of Immunotherapy
Susan Blumel, RN, BSN, of the University of Nebraska Medical Center, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, of Stanford Health Center, discuss immunotherapy,...
Jonathan W. Friedberg, MD, on Follicular Lymphoma: Novel Combination Therapies
Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses treatments that enhance progression-free and overall survival and clear minimal residual disease...
